XML 22 R48.htm IDEA: XBRL DOCUMENT v2.4.0.8
Revenues (Narrative) (Details) (USD $)
 3 Months Ended 12 Months Ended
Dec. 31, 2011
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Product Revenues [Abstract]        
Product revenue, sales allowances $ 400,000      
Net product revenue   31,100,698 47,944,031 50,893,794
Accrued liabilities, current   5,509,917 5,264,806  
Other Revenues [Abstract]        
Other revenues, milestone method   0    
Product Sales Related Accruals - Rebates, Product Returns, Administrative Fees and Service Fees
        
Product Revenues [Abstract]        
Accrued liabilities, current   2,400,000 3,400,000  
Product, Omeclamox-Pak
        
Product Revenues [Abstract]        
Net product revenue   1,045,815 0 0
Product, Caldolor
        
Product Revenues [Abstract]        
Gross product revenue   2,900,000 1,300,000 300,000
Net product revenue   2,089,655 992,110 (78,134)
Product, Acetadote, Generic
        
Product Revenues [Abstract]        
Net product revenue   9,200,000 300,000  
Product Sales Related Allowances - Chargebacks, Cash Discounts and Damaged Goods
        
Product Revenues [Abstract]        
Accounts receivable, allowances, current   600,000 200,000  
Collaborative Arrangement, Amended International Agreement
        
Other Revenues [Abstract]        
Other revenue, agreements   6    
Other revenues, milestone method   600,000    
Other revenue, potential upfront payments related to regulatory approval   600,000    
Other revenue, potential upfront payment related to product sales   4,000,000    
Collaborative Arrangement, Federal Small Business Grant Programs
        
Other Revenues [Abstract]        
Other revenues, grants   100,000 100,000 100,000
Collaborative Arrangement, Licensing Agreement with Harbin Gloria Pharmaceuticals Co. Ltd. | Acetadote and Caldolor
        
Other Revenues [Abstract]        
Other revenues, proceeds from sale of intangible assets   700,000    
Collaborative Arrangement, Licensing Agreement with Harbin Gloria Pharmaceuticals Co. Ltd. | Acetadote and Caldolor | Milestone Method Future Revenue, Receipt of Regulatory Notice Related to Conducting Clinical Trials
        
Other Revenues [Abstract]        
Other revenues, milestone method, future revenue upon achieving milestones   700,000    
Collaborative Arrangement, Licensing Agreement with Harbin Gloria Pharmaceuticals Co. Ltd. | Acetadote and Caldolor | Milestone Method Future Revenue, Receipt of Regulatory Notice on Approval of Acetadote and Caldolor in China
        
Other Revenues [Abstract]        
Other revenues, milestone method, future revenue upon achieving milestones   $ 1,100,000